PatientsVille.com Logo


Maximum Medical Research Studies

Up-to-date List of Maximum Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Maximum Medical Research Studies

Rank Status Study
1 Recruiting Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy
Condition: Minimally Sedated Patient Undergoing Colonoscopy
Interventions: Procedure: half-maximal pressure;   Procedure: maximal pressure;   Device: Suction Unit
Outcome Measures: cecal intubation time;   infused water amount;   aspirated water amount;   pain score;   suction marks on the mucosa
2 Recruiting Prediction of Maximum Tolerated Dose for Hydroxyurea Treatment in Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Hydroxyurea
Outcome Measures: Time to patients reaching the Maximum tolerated dose (MTD) of the medication;   Safety Analysis
3 Recruiting Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
Condition: Solid Tumour
Intervention: Drug: CG200745
Outcome Measure: To determine the Maximum tolerated dose in Single dose
4 Recruiting Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
Outcome Measures: Maximum Tolerated Dose;   Adverse events;   Overall Survival;   Response Rate;   Duration of response;   Time to response
5 Unknown  Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment
Condition: Erectile Dysfunction
Interventions: Drug: Sildenafil 100 mg;   Drug: Tadalafil 20 mg;   Drug: Combination half of maximal dose for sildenafil & tadalafil
Outcome Measures: International Index of Erectile Function-Erectile Dysfunction (IIEF-ED) Domain Score;   Erection Hardness Scale
6 Recruiting An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Condition: Solid Tumors
Intervention: Drug: E7389-LF
Outcome Measures: Maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF);   Dosing frequency of E7389 liposomal formulation (E7389-LF);   Safety and Tolerability of E7389-LF;   Pharmacokinetics of E7389-LF;   Evidence of efficacy by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;   Effect of E7389-LF on cardiac repolarization
7 Unknown  A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: Docetaxel-PNP
Outcome Measures: The Maximum tolerated dose (MTD) of Docetaxel-PNP;   The recommended phase II dose of Docetaxel-PNP;   The Dose Limiting Toxicity (DLT);   The pharmacokinetics of Docetaxel-PNP on Day 1 of 1st cycle (AUC, CL, T1/2, Tmax, Cmax, Vdss);   Objective response rate
8 Unknown  The Impact of High Intensity Exercise Upon EPC Number and Function in Young Women
Condition: Exercise Anaphylaxis
Interventions: Behavioral: Sprint interval exercise;   Behavioral: Maximal continuous exercise
Outcome Measures: Maximal oxygen uptake;   Heart rate variability;   Endothelial progenitor cell function;   Flow mediated dialtion;   Arterial stiffness;   Circulating angiogenic cell numbers
9 Recruiting A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Givinostat
Outcome Measures: Part A: Maximum Tolerated Dose;   Part B: Preliminary efficacy after 3 cycles of treatment;   Part A: Safety and tolerability;   Part B: Safety and tolerability after 3 cycles of treatment;   Part A: characterization of pharmacokinetic;   Part B: characterization of pharmacokinetic;   Part A: preliminary efficacy after 3 and 6 cycles of treatment;   Part B: preliminary efficacy of Givinostat at the Maximum Tolerated Dose after 6 cycles.;   Part B: safety and tolerability after 6 cycles
10 Recruiting A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Condition: Acute Schizophrenia
Intervention: Drug: NW-3509a
Outcome Measures: Evaluate safety and tolerability and Maximum tolerated dose of NW-3509a in Healthy Male Volunteers;   To determine the pharmacokinetics of NW-3509a at doses tested
11 Unknown  Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement
Conditions: Coronary Artery Disease;   Myocardial Ischemia
Interventions: Other: Maximal Hyperemia with Adenosine Followed by Nicorandil;   Other: Maximal Hyperemia with Nicorandil Followed by Adenosine
Outcome Measures: Fractional Flow Reserve at Maximal Hyperemia;   Time to Maximal Hyperemia;   Changes in Heart Rate
12 Unknown  Effect of Exercise With Low Intensity and Longer Duration Versus High Intensity Interval Training
Condition: Healthy Subjects
Intervention: Other: endurance exercise of different duration and intensity
Outcome Measures: changes in maximal oxygen uptake;   endurance performance;   health effects
13 Not yet recruiting Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers
Condition: PAH
Intervention: Drug: TransCon PEG treprostinil
Outcome Measures: Incidence of treatment-emergent AEs;   Maximum tolerated dose;   Treatment-emergent changes in clinical laboratory results;   Treatment-emergent changes in vital signs;   Area under the concentration versus time curve: (AUC);   Maximum observed plasma concentration: Cmax;   Time to Maximum observed plasma concentration: Tmax
14 Recruiting Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: AZD1208
Outcome Measures: Part A: Number of patients with dose limiting toxicities (DLTs) [Maximum Tolerated Dose (MTD) is defined as the Maximum dose level below the dose level at which ≥ 33 % of at least 6 patients of a cohort experience DLTs during cycle 1.];   Part B: Number of patients with Complete Remission (CR) or CR with incomplete blood count recovery (CRi);   Part A and B: Number of patients with adverse events and serious adverse events;   Part A and B: Description of the pharmacokinetics (PK) of AZD1208 in terms of area under plasma concentration-time curve(AUC), Maximum plasma concentration (Cmax), and time to Maximum plasma concentration (Tmax);   Part A and B: Description of urine pharmacokinetics (PK) of AZD1208 in terms of the cumulative amount of drug excreted unchanged into urine from zero to time and renal clearance;   Part A and B: Number of patients with response of Complete Remission(CR), CR with incomplete blood count recovery, Partial Remission, or Morphologic Leukemia-Free;   Part B: Duration of CR or CRi based on time from first documentation of CR to relapse
15 Recruiting Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
Condition: Oncology
Interventions: Drug: BAY94-9343;   Drug: BAY94-9343 (Expansion);   Drug: BAY94-9343 (1.8 mg/kg);   Drug: BAY94-9343 (2.2 mg/kg)
Outcome Measures: Number of participants with treatment emergent adverse events;   Determination of the Pharmakokinetic profile of BAY94-9343 and its metabolites;   Biomarker evaluation: mesothelin plasma and Cytokeratin 18 (CK18) levels;   Tumor response: assessment of best response, TTP (time to progression), and PFS (progression free survival) according to RECIST (Response Evaluation Criteria in Solid Tumours) 1.1;   Immunogenicity assessment: assessment of anti BAY 94-9343 antibodies;   Biomarker evaluation - Levels of mesothelin expression in tumor tissue
16 Recruiting To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
Condition: Solid Tumors
Intervention: Drug: CEP-37440
Outcome Measures: Response Evaluation Criteria in Solid Tumors (RECIST v1.1);   Time to Response (TTR);   Number of participants with adverse events;   Time to Progression (TTP);   Progression-free Survival (PFS);   Time to New Metastases (TTNM)
17 Recruiting A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INC424;   Drug: BKM120
Outcome Measures: Incidence of dose limiting toxicities;   Frequency of adverse events;   Frequency of serious adverse events;   Abnormalities in vital signs;   Laboratory test values including Imaging (electrocardiograms (ECGs), abdominal MRI/CT, ECHO/MUGA;   Maximum plasma concentration (Cmax);   Maximum plasma concentration time (Tmax);   Area under the plasma concentration time curve (AUC);   Duration of adverse events;   Severity of adverse events;   Duration of serious adverse events;   Severity of serious adverse events
18 Recruiting Value of Ankle Pressure Index After Maximal Exercise Tests
Condition: Cardiovascular Diseases
Intervention: Other: Exercise test
Outcome Measures: Mean value of post exercise ABI by age categories;   Prevalence of Morbi-mortality through self completed questionnaires
19 Recruiting First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Biological: BAY2010112
Outcome Measures: Number of participants with Adverse Events as a Measure of Safety and Tolerability;   Maximum Tolerated Dose (MTD);   Maximum drug concentration (Cmax) of BAY2010112 in serum after single and multiple doses administration;   Area under the concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY2010112;   Tumor response;   Prostate-specific antigen (PSA) response
20 Not yet recruiting Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma
Conditions: Glioblastoma;   Astrocytoma
Intervention: Radiation: Rhenium Liposome Treatment
Outcome Measures: Maximum Tolerated Dose;   Dose Distribution;   Response rate;   Survival

These studies may lead to new treatments and are adding insight into Maximum etiology and treatment.

A major focus of Maximum research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Maximum